Orthotopic administration of 213Bi-Bevacizumab inhibits progression of PC3 xenografts in the prostate
Tumour growth requires development of new blood vessels – a process known as
angiogenesis. The anti-angiogenic monoclonal antibody Bevacizumab (BZ), which targets
vascular endothelial growth factor (VEGF), is now part of the standard treatment for
advanced colorectal cancer. Castrate resistant prostate cancers also express VEGF but are
only marginally responsive to BZ alone or in combination with chemotherapy. Targeted
alpha-radioimmunotherapy (TAT) is an emerging technology that can safely enhance
immunotherapy for improved cancer control. TAT targeting can be further enhanced through
orthotopic delivery. In this preliminary study we investigate orthotopic TAT for the control of
early-stage prostate cancer PC3 xenografts using alpha radio-labelled BZ (213Bi-BZ). Results
indicate that orthotopic administration of 213Bi- BZ greatly improves the early control of
organ confined prostate cancer compared to BZ alone (P<0.01).
RIZVI S.M.A.;
ALLEN B.J.;
LEE C.S.;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
APOSTOLIDIS Christos;
CLARKE R.A.;
2012-10-15
FUTURE MEDICINE LTD
JRC70139
1750-743X,
http://www.futuremedicine.com/doi/abs/10.2217/imt.12.42?journalCode=imt,
https://publications.jrc.ec.europa.eu/repository/handle/JRC70139,
Additional supporting files
| File name | Description | File type | |
|---|
